At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02367 GIANT BIOGENE
Noon Closed 06-30 12:05:00
26.420
-0.520
-1.93%
High27.660Low26.400Vol1.85M
Open27.020D1 Closing26.940Amplitude4.68%
Mkt Cap28.06BTradable Cap28.06BTotal Shares1.06B
T/O49.82MT/O Rate0.17%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜Giant Biogene Rises 6.43% in Regular Trading, 618 Promotion Results Beat Expectations Amid Sector-Wide Strength
Market Focus  ·  06-29 13:02
Movement Alert｜Giant Biogene Rises 6.43% in Regular Trading, 618 Promotion Results Beat Expectations Amid Sector-Wide Strength
Movement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure
Market Focus  ·  06-25
Movement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure
Giant Biogene Shares Surge Over 6% in Early Trading, CICC Reiterates Outperform Rating
Deep News  ·  06-24
Giant Biogene Shares Surge Over 6% in Early Trading, CICC Reiterates Outperform Rating
Movement Alert｜Giant Biogene Rises 5.45% in Regular Trading, Crosslinked Recombinant Collagen Implant Approval Boosts Market Confidence
Market Focus  ·  06-24
Movement Alert｜Giant Biogene Rises 5.45% in Regular Trading, Crosslinked Recombinant Collagen Implant Approval Boosts Market Confidence
Giant Biogene Shares Surge Over 4% Intraday Following Approval of Key Medical Device
Stock News  ·  06-24
Giant Biogene Shares Surge Over 4% Intraday Following Approval of Key Medical Device
CICC Maintains "Outperform Industry" Rating on Giant Biogene, Adjusts Target Price to HK$40
Stock News  ·  06-22
CICC Maintains "Outperform Industry" Rating on Giant Biogene, Adjusts Target Price to HK$40
Hong Kong Market Announcement Highlights: Three IPOs Launch Including Optical Module Supplier, Lenovo Plans $2 Billion Convertible Bond Issue
Stock News  ·  06-18
Hong Kong Market Announcement Highlights: Three IPOs Launch Including Optical Module Supplier, Lenovo Plans $2 Billion Convertible Bond Issue
Giant Biogene Unit Gets Registration Certificate for Neck Wrinkle Injection
MT Newswires Live  ·  06-17
Giant Biogene Unit Gets Registration Certificate for Neck Wrinkle Injection
Giant Biogene Secures NMPA Approval for World’s First Cross-linked Recombinant Type III Collagen Neck Filler
Bulletin Express  ·  06-17
Giant Biogene Secures NMPA Approval for World’s First Cross-linked Recombinant Type III Collagen Neck Filler
Giant Biogene Secures Medical Device Registration for Its Cross-Linked Recombinant Collagen Implant
Stock News  ·  06-17
Giant Biogene Secures Medical Device Registration for Its Cross-Linked Recombinant Collagen Implant
Giant Biogene Holding Co Ltd - Certificate Issued by China National Medical Products Administration
THOMSON REUTERS  ·  06-17
Giant Biogene Holding Co Ltd - Certificate Issued by China National Medical Products Administration
Giant Biogene Holding Co - Receives China Medical Device Registration for Cross-Linked Recombinant Collagen Implant
THOMSON REUTERS  ·  06-17
Giant Biogene Holding Co - Receives China Medical Device Registration for Cross-Linked Recombinant Collagen Implant
Giant Biogene wins China NMPA approval for neck-wrinkle recombinant collagen filler
Reuters  ·  06-17
Giant Biogene wins China NMPA approval for neck-wrinkle recombinant collagen filler
Assessing Giant Biogene Holding (SEHK:2367) Valuation After Approving Final And Special Dividends
Simply Wall St.  ·  06-09
Assessing Giant Biogene Holding (SEHK:2367) Valuation After Approving Final And Special Dividends
The Hidden Challenges Behind JiaKai Biotech's IPO: A Closer Look at the 'Chip' of Cosmetics
Deep News  ·  06-05
The Hidden Challenges Behind JiaKai Biotech's IPO: A Closer Look at the 'Chip' of Cosmetics
Giant Biogene Reports Stable Capital Structure for May 2026; 0.67 Million Share Options Lapse
Bulletin Express  ·  06-04
Giant Biogene Reports Stable Capital Structure for May 2026; 0.67 Million Share Options Lapse
Hong Kong Cosmetics Stocks Surge, Domestic Brands Poised for Strong 618 Finish
Stock News  ·  06-01
Hong Kong Cosmetics Stocks Surge, Domestic Brands Poised for Strong 618 Finish
Movement Alert｜Giant Biogene Rises 5.33% in Regular Trading, Shareholders Approve Generous Dividend of RMB 1.2104 Per Share
Market Focus  ·  05-29
Movement Alert｜Giant Biogene Rises 5.33% in Regular Trading, Shareholders Approve Generous Dividend of RMB 1.2104 Per Share
Giant Biogene Announces RMB0.539 Final Dividend per Share for FY2025
Bulletin Express  ·  05-28
Giant Biogene Announces RMB0.539 Final Dividend per Share for FY2025
Giant Biogene to Appoint KPMG as Auditor, Ending Seven-Year Engagement with EY
Bulletin Express  ·  05-28
Giant Biogene to Appoint KPMG as Auditor, Ending Seven-Year Engagement with EY

Introduction

Company Name.
GIANT BIOGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Giant Biogene Holding Co Ltd is an investment holding company primarily engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products. The Company's main products include professional skin treatment products such as functional skincare products and medical dressings, as well as functional foods and others. The Company primarily conducts its businesses in domestic market.
Issue price:
--